Terug
Dagbereik
€ 25,82
€ 27,83
52-Weeksbereik
€ 9,60
€ 30,58
Volume
1.533.123
50D / 200D Gem.
€ 25,21
/
€ 21,69
Vorige Slotkoers
€ 27,06
Koershistorie
Financiële Trends
Sectorvergelijking
vs Healthcare sector mediaan (626 peers)
| Metriek | Aandeel | Sector Mediaan |
|---|---|---|
| P/E | -14,8 | 0,4 |
| P/B | 8,7 | 2,9 |
| ROE % | -73,9 | 3,7 |
| Net Margin % | — | 3,8 |
| Rev Growth 5Y % | — | 10,0 |
| D/E | 0,3 | 0,2 |
Insider Trading Activity
20 transactions
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| Feb 2, 2026 |
Bush Tia L
Chief Technology & Quality Ofc
|
grant | 175.000 | — | — |
| Feb 1, 2026 |
Bush Tia L
Chief Technology & Quality Ofc
|
other | 8.549 | € 24,57 | € 210.049 |
| Dec 8, 2025 |
Accardi Mario Alberto
President, Orexin Program
|
other | 10.000 | € 9,53 | — |
| Dec 8, 2025 |
Accardi Mario Alberto
President, Orexin Program
|
sell | 10.000 | € 30,00 | € 300.000 |
| Nov 17, 2025 |
HUSSAIN IQBAL J
General Counsel
|
other | 12.000 | € 5,84 | — |
| Nov 17, 2025 |
HUSSAIN IQBAL J
General Counsel
|
sell | 6.000 | € 27,64 | € 165.835 |
| Nov 1, 2025 |
Accardi Mario Alberto
President, Orexin Program
|
other | 593 | € 24,90 | € 14.766 |
| Sep 10, 2025 |
HUSSAIN IQBAL J
General Counsel
|
other | 40.000 | € 5,84 | — |
| Sep 10, 2025 |
HUSSAIN IQBAL J
General Counsel
|
sell | 20.000 | € 22,00 | € 440.000 |
| Sep 9, 2025 |
HUSSAIN IQBAL J
General Counsel
|
other | 40.000 | € 5,84 | — |
| Sep 9, 2025 |
HUSSAIN IQBAL J
General Counsel
|
sell | 20.000 | € 20,01 | € 400.102 |
| Aug 1, 2025 |
Accardi Mario Alberto
President, Orexin Program
|
other | 597 | € 17,17 | € 10.250 |
| Jul 29, 2025 |
Accardi Mario Alberto
President, Orexin Program
|
sell | 8.322 | € 15,23 | € 126.751 |
| Jul 25, 2025 |
Weinhoff Gregory M
Chief Business Officer
|
other | 20.000 | € 3,85 | — |
| Jul 25, 2025 |
Weinhoff Gregory M
Chief Business Officer
|
sell | 10.000 | € 15,56 | € 155.598 |
| Jul 21, 2025 |
SAHA SAURABH
Chief Executive Officer
|
other | 110.000 | € 3,85 | — |
| Jul 21, 2025 |
SAHA SAURABH
Chief Executive Officer
|
sell | 55.000 | € 15,92 | € 875.600 |
| Jul 15, 2025 |
HUSSAIN IQBAL J
General Counsel
|
other | 12.000 | € 5,84 | — |
| Jul 15, 2025 |
HUSSAIN IQBAL J
General Counsel
|
sell | 6.000 | € 14,93 | € 89.567 |
| Jun 24, 2025 |
Accardi Mario Alberto
President, Orexin Program
|
other | 30.000 | € 3,85 | — |
Belangrijkste Punten
Debt/Equity of 0,29 — conservative balance sheet
Negative free cash flow of -142,09M
Groei
Revenue Growth (5Y)
N/A
Revenue (1Y)-100,00%
Earnings (1Y)N/A
FCF Growth (3Y)N/A
Kwaliteit
Return on Equity
-73,93%
ROIC-29,07%
Net MarginN/A
Op. MarginN/A
Veiligheid
Debt / Equity
0,29
Current Ratio9,25
Interest Coverage-19,93
Waardering
P/E Ratio
-14,79
P/B Ratio8,68
EV/EBITDAN/A
Dividend Yield0,00%
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | -100,00% | Revenue Growth (3Y) | N/A |
| Earnings Growth (1Y) | N/A | Earnings Growth (3Y) | N/A |
| Revenue Growth (5Y) | N/A | Earnings Growth (5Y) | N/A |
| Profitability | |||
| Revenue (TTM) | 0,0 | Net Income (TTM) | -235,76M |
| ROE | -73,93% | ROA | -40,87% |
| Gross Margin | N/A | Operating Margin | N/A |
| Net Margin | N/A | Free Cash Flow (TTM) | -142,09M |
| ROIC | -29,07% | FCF Growth (3Y) | N/A |
| Safety | |||
| Debt / Equity | 0,29 | Current Ratio | 9,25 |
| Interest Coverage | -19,93 | Dividend Yield | 0,00% |
| Valuation | |||
| P/E Ratio | -14,79 | P/B Ratio | 8,68 |
| P/S Ratio | N/A | PEG Ratio | -0,26 |
| EV/EBITDA | N/A | Dividend Yield | 0,00% |
| Market Cap | 3,49B | Enterprise Value | 3,22B |
Income Statement
Annual, most recent first
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | 0,0 | 6,85M | 0,0 | 0,0 | 0,0 |
| Net Income | -235,76M | -151,09M | -216,21M | -381,90M | -10,66M |
| EPS (Diluted) | -2,06 | -1,57 | -2,31 | -4,24 | -0,08 |
| Gross Profit | 0,0 | 6,85M | 0,0 | 0,0 | 0,0 |
| Operating Income | -201,06M | -171,28M | -212,26M | -374,87M | -10,44M |
Balance Sheet
Annual, most recent first
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Total Assets | 576,80M | 360,25M | 444,31M | 629,64M | 11,72M |
| Total Liabilities | 175,25M | 124,00M | 108,14M | 138,08M | 8,62M |
| Shareholders' Equity | 401,55M | 236,24M | 336,17M | 491,55M | 3,10M |
| Total Debt | 117,23M | 84,59M | 69,80M | 75,70M | 5,63M |
| Cash & Equivalents | 383,22M | 128,03M | 393,64M | 595,08M | 7,23M |
| Current Assets | 536,41M | 315,09M | 437,75M | 628,77M | 11,17M |
| Current Liabilities | 58,00M | 39,39M | 38,34M | 24,64M | 8,62M |